Results 91 to 100 of about 189,087 (191)

Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia

BMC Ophthalmology, 2018
Background To assess visual outcomes over 24 months in patients with neovascular age-related macular degeneration (nAMD) who initiated intravitreal aflibercept therapy under a treat-and-extend (TE) regimen in real-world settings.
Polona Jaki Mekjavić, Bogdan Gregorčič, Cvetka Oberč, Slava Podgoršek   +3 more
doaj   +1 more source

Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration

Türk Oftalmoloji Dergisi, 2019
Objectives:To assess outcomes of a risk-based algorithm-guided treatment protocol for neovascular age-related macular degeneration.Materials and Methods:Two hundred and ten eyes of 184 patients managed with anti-vascular endothelial growth factor (anti ...
Murat Karaçorlu, Mümin Hocaoğlu, Serra Arf, M. Giray Ersöz, Işıl Sayman Muslubaş   +4 more
doaj   +1 more source

Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment

Patient Preference and Adherence, 2020
Takeshi Joko,1 Yoshimi Nagai,2 Ryusaburo Mori,3 Koji Tanaka,3 Yuji Oshima,4 Yusuke Hikichi,5 Tetsushi Komori,6 Joao Carrasco,7 Martine C Maculaitis,8 Oliver Will,8 Kathleen Beusterien,8 Kanji Takahashi2 1Department of Ophthalmology, Matsuyama Red Cross ...
Joko T, Nagai Y, Mori R, Tanaka K, Oshima Y, Hikichi Y, Komori T, Carrasco J, Maculaitis MC, Will O, Beusterien K, Takahashi K   +11 more
doaj  

Treat-and-extend regimen for management of neovascular agerelated macular degeneration: recommendations from the Hong Kong Retina Expert Panel [PDF]

, 2019
Antivascular endothelial growth factor (anti-VEGF) agents are a safe and effective treatment option for neovascular age-related macular degeneration (nAMD).
Chan, Y, Chung, DCY, Fung, NSK, Ho, M, Ko, CKL, Lai, TYY, Leung, JWY, Mohammed, S, Ng, DSC, Sin, HPY, Tang, HHY, Wong, IYH, Wong, RLM   +12 more
core  

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

Pharmaceuticals
Our objective was to evaluate changes in patient-reported outcome measures using the NEI-VFQ 25 questionnaire during a treat and extend regimen in naive neovascular Age-Related Macular Degeneration patients, and its correlation with anatomical and ...
Pablo Almuiña-Varela, Laura García-Quintanilla, María José Rodríguez-Cid, María Gil-Martínez, Maximino J. Abraldes, Francisco Gómez-Ulla, Ana Estany-Gestal, Jorge Miguel Alcántara-Espinosa, Maribel Fernández-Rodríguez, Anxo Fernández-Ferreiro   +9 more
doaj   +1 more source

Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion. 72-Week Results from the BALATON and COMINO Trials [PDF]

To assess the efficacy, durability, and safety of dual angiopoietin-2/VEGF inhibition with faricimab dosed per a modified treat-and-extend-based regimen in patients with retinal vein occlusion.Single-arm treatment period after a randomized, double-masked,
Abreu Francis, Arrisi Pablo, Danzig Carl J, Dinah Christiana, Ghanchi Faruque, Hattenbach Lars-Olof, Khanani Arshad M, Lai Timothy Y Y, Liu Ying, Paris Liliana P, Retiere Anne-Cecile, Schlottmann Patricio G, Shimura Masahiko, Tóth-Molnár Edit, Willis Jeffrey R   +14 more
core   +1 more source

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration

Clinical Ophthalmology, 2019
Justus G Garweg1,21Swiss Eye Institute, Rotkreuz, and Berner Augenklinik Am Lindenhofspital, Bern, Switzerland; 2Department of Ophthalmology, Inselspital, University of Bern, Bern, SwitzerlandPurpose: To review published evidence for a treatment interval
Garweg JG
doaj  

One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

Scientific Reports
This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD).
Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Makiko Nakayama, Yuto Watanabe, Akiko Yamamoto, Yu Wakatsuki, Hajime Onoe, Sorako Wakugawa, Nobuhiro Terao, Taiji Hasegawa, Moeko Kawai, Ruka Maruko, Kanako Itagaki, Jyunichiro Honjo, Annabelle A. Okada, Ryusaburo Mori, Hideki Koizumi, Tomohiro Iida, Tetsuju Sekiryu   +21 more
doaj   +1 more source

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

International Journal of Retina and Vitreous
Background Intravitreal faricimab, a bispecific antibody targeting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), was recently introduced for the treatment of neovascular age-related macular degeneration (nAMD), diabetic ...
Gabriela Grimaldi, Giuseppe Cancian, Arianna Paris, Michele Clerici, Giulio Volpe, Moreno Menghini   +5 more
doaj   +1 more source

Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. [PDF]

Invest Ophthalmol Vis Sci, 2023
Trejo Corona S, Villanueva Boone C, Ali AM, Moore C, Brown A, Munoz J, Aaberg T, Schefler AC, ARRT Study Group.   +8 more
europepmc   +1 more source